Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence
Open Access
- 1 January 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 113-124
- https://doi.org/10.2147/copd.s274846
Abstract
Metered dose inhalers (MDIs) are one of the most common device types for delivering inhaled therapies. However, there are several technical challenges in development and drug delivery of these medications. In particular, suspension-based MDIs are susceptible to suspension heterogeneity, in vitro drug–drug interactions, and patient handling errors, which may all affect drug delivery. To overcome these challenges, new formulation approaches are required. The AerosphereTM inhaler, formulated using co-suspension delivery technology, combines drug crystals with porous phospholipid particles to create stable, homogenous suspensions that dissolve once they reach the airways. Two combination therapies using this technology have been developed for the treatment of COPD: glycopyrrolate/formoterol fumarate (GFF MDI; dual combination) and budesonide/glycopyrrolate/formoterol fumarate (BGF MDI; triple combination). Here, we review the evidence with a focus on studies assessing dose delivery, lung deposition, and effects on airway geometry. In vitro assessments have demonstrated that the Aerosphere inhaler provides consistent dose delivery, even in the presence of simulated patient handling errors. Combination therapies delivered with this technology also show a consistent fine particle fraction (FPF) and an optimal particle size distribution for delivery to the central and peripheral airways even when multiple drugs are delivered via the same inhaler. Studies using gamma scintigraphy and functional respiratory imaging have demonstrated that GFF MDI is effectively deposited in the central and peripheral airways, and provides clinically meaningful benefits on airway volume and resistance throughout the lung. Overall, studies suggest that the Aerosphere inhaler, formulated using co-suspension delivery technology, may offer advantages over traditional formulations, including consistent delivery of multiple components across patient handling conditions, optimal particle size and FPF, and effective delivery to the central and peripheral airways. Future studies may provide additional evidence to further characterize the clinical benefits of these technical improvements in MDI drug delivery.Keywords
This publication has 59 references indexed in Scilit:
- Fine Particle Profile of Fluticasone Propionate/Formoterol Fumarate Versus Other Combination Products: the DIFFUSE StudyCombination Products in Therapy, 2013
- Standardization of Techniques for Using Planar (2D) Imaging for Aerosol Deposition Assessment of Orally Inhaled ProductsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2012
- Aerosol Deposition in Health and DiseaseJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2012
- Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patientsAnnals of Allergy, Asthma & Immunology, 2012
- Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2011
- Inhaler mishandling remains common in real life and is associated with reduced disease controlRespiratory Medicine, 2011
- Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD PatientsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Inspiratory flow rates at different levels of resistance in elderly COPD patientsEuropean Respiratory Journal, 2008
- Methods to identify drug deposition in the lungs following inhalationBritish Journal of Clinical Pharmacology, 2001
- Methods to determine lung distribution of inhaled drugs – could gamma scintigraphy be the gold standard?British Journal of Clinical Pharmacology, 2000